摘要
目的探讨不同配比的哌拉西林/他唑巴坦治疗医院获得性肺炎(HAP)的临床疗效、细菌学疗效、安全性与经济学效果。方法选取HAP患者120例,随机分为两组,每组各60例,分别使用特治星(4.0g哌拉西林+0.5g他唑巴坦,8∶1的配比)和佐朋(1.0g哌拉西林+0.25g他唑巴坦,4∶1的配比)治疗,连续治疗两周;治疗后比较两组的临床疗效、细菌学疗效、安全性与经济学效果。结果特治星组与佐朋组临床有效率分别为81.7%、80.0%,细菌清除率分别为78.3%、75.0%,差异均无统计学意义;特治星组与佐朋组的不良反应发生率分别为11.7%、3.3%,日均治疗费用分别为(360.5±60.8)元、(192.0±42.5)元,差异均有统计学意义(P<0.05)。结论佐朋与特治星治疗医院获得性肺炎疗效相当,但佐朋的剂量更小、不良反应发生率更低、安全性更高,日均治疗费用更低、更符合用药经济学原理。
OBJECTIVE To explore the clinical efficacy,bacteriological efficacy,safety,and economic effect of treating hospital acquired pneumonia(HAP) with different proportions of piperacillin/tazobactam.METHODS A total of 120 patients with HAP were selected and divided into 2 groups randomly,60 cases in each group,retrospectively treated by tazocin(4.0g piperacillin plus 0.5g tazobactam,in 8∶1 ratio) and Zuo Peng(1.0g piperacillin plus 0.25g tazobactam,in 4∶1 ratio) for 2 weeks;the clinical and bacteriological efficacy,safety and economic effect of the 2 groups were compared after treatment.RESULTS The effective rates of Tazocin group and Zuo Peng group were 81.7% and 80.0% respectively,and the bacterial clearance rates were 78.3% and 75.0%,there were no significant differences;the incidence rates of adverse reactions of Tazocin group and Zuo Peng group were 11.7% and 3.3%,and average costs for daily treatment were(360.5± 60.8) yuan and(192.0± 42.5)yuan,there were significant differences(P0.05 or P0.01).CONCLUSION The effect of Zuo Peng equals to Tarocin on the treatment of HAP,with the dose smaller,the incidence of adverse reaction lower,the safety higher,and with less costs for daily treatment,which is more in line with the principles of pharmacy economics.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2012年第9期1897-1899,共3页
Chinese Journal of Nosocomiology